📊 CODX Key Takeaways
Is Co-Diagnostics, Inc. (CODX) a Good Investment?
Co-Diagnostics exhibits severe operational distress with collapsing profitability despite healthy gross margins, indicating fundamental business model failure. The company is burning substantial cash with negative operating cash flow of -$22.9M against minimal revenue of $358.6K, making the current trajectory unsustainable even with adequate liquidity reserves.
Co-Diagnostics shows extremely weak fundamentals, with negligible revenue relative to its cost base and very large operating and net losses. While the balance sheet is currently lightly levered and still holds meaningful cash, the scale of operating cash burn versus cash on hand indicates poor sustainability unless the company sharply reduces expenses or rebuilds revenue. Growth quality appears very weak because there is no meaningful top-line expansion supporting the business model.
Why Buy Co-Diagnostics, Inc. Stock? CODX Key Strengths
- Strong liquidity position with $11.4M cash and 3.81x current ratio
- Healthy gross margin of 77.7% indicates viable product economics at unit level
- Conservative capital structure with low debt-to-equity ratio of 0.05x
- Strong gross margin indicates the core product economics can be attractive at higher scale
- Balance sheet leverage is low, with modest long-term debt and substantial equity relative to liabilities
- Liquidity ratios remain solid in the near term, reducing immediate balance-sheet stress
CODX Stock Risks: Co-Diagnostics, Inc. Investment Risks
- Catastrophic operating losses of -$23.6M on near-zero revenue indicates severe commercialization failure
- Negative operating cash flow of -$22.9M annually will deplete cash reserves in approximately 5 quarters at current burn rate
- Revenue essentially flat YoY with no growth trajectory visible; business appears stalled or in decline
- Operating margin of -6588% and net margin of -5898% are unsustainable and indicate the company cannot convert sales into profits
- Negative ROE of -53.1% and ROA of -47.3% demonstrate severe capital inefficiency
- Revenue is extremely low and effectively flat, showing little evidence of commercial traction
- Operating and net margins are deeply negative, indicating a severely mismatched cost structure
- Operating cash flow and free cash flow are heavily negative relative to cash reserves, creating significant runway risk
Key Metrics to Watch
- Quarterly revenue trend - any stabilization or decline acceleration
- Operating cash burn rate - critical to cash runway estimation
- Operating expense reduction progress - evidence of cost control efforts
- Path to profitability or strategic pivots - restructuring or business model changes
- Quarterly revenue growth and whether sales scale meaningfully above the current base
- Cash burn trend, especially operating cash flow relative to cash and equivalents
Co-Diagnostics, Inc. (CODX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.81x current ratio provides a solid financial cushion.
CODX Profit Margin, ROE & Profitability Analysis
CODX vs Healthcare Sector: How Co-Diagnostics, Inc. Compares
How Co-Diagnostics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Co-Diagnostics, Inc. Stock Overvalued? CODX Valuation Analysis 2026
Based on fundamental analysis, Co-Diagnostics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Co-Diagnostics, Inc. Balance Sheet: CODX Debt, Cash & Liquidity
CODX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Co-Diagnostics, Inc.'s revenue has declined by 96% over the 5-year period, indicating business contraction. The most recent EPS of $-37.22 indicates the company is currently unprofitable.
CODX Revenue Growth, EPS Growth & YoY Performance
CODX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $145.4K | -$5.9M | $-0.16 |
| Q2 2025 | $162.9K | -$7.5M | $-0.23 |
| Q1 2025 | $50.3K | -$7.5M | $-0.24 |
| Q3 2024 | $641.1K | -$5.8M | $-0.20 |
| Q2 2024 | $197.8K | -$5.8M | $-0.25 |
| Q1 2024 | $467.9K | -$5.8M | $-0.20 |
| Q3 2023 | $2.5M | -$1.4M | $-0.04 |
| Q2 2023 | $197.8K | -$2.7M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Co-Diagnostics, Inc. Dividends, Buybacks & Capital Allocation
CODX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Co-Diagnostics, Inc. (CIK: 0001692415)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CODX
What is the AI rating for CODX?
Co-Diagnostics, Inc. (CODX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CODX's key strengths?
Claude: Strong liquidity position with $11.4M cash and 3.81x current ratio. Healthy gross margin of 77.7% indicates viable product economics at unit level. ChatGPT: Strong gross margin indicates the core product economics can be attractive at higher scale. Balance sheet leverage is low, with modest long-term debt and substantial equity relative to liabilities.
What are the risks of investing in CODX?
Claude: Catastrophic operating losses of -$23.6M on near-zero revenue indicates severe commercialization failure. Negative operating cash flow of -$22.9M annually will deplete cash reserves in approximately 5 quarters at current burn rate. ChatGPT: Revenue is extremely low and effectively flat, showing little evidence of commercial traction. Operating and net margins are deeply negative, indicating a severely mismatched cost structure.
What is CODX's revenue and growth?
Co-Diagnostics, Inc. reported revenue of $358.6K.
Does CODX pay dividends?
Co-Diagnostics, Inc. does not currently pay dividends.
Where can I find CODX SEC filings?
Official SEC filings for Co-Diagnostics, Inc. (CIK: 0001692415) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CODX's EPS?
Co-Diagnostics, Inc. has a diluted EPS of $-0.62.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CODX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Co-Diagnostics, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CODX stock overvalued or undervalued?
Valuation metrics for CODX: ROE of -53.1% (sector avg: 15%), net margin of -5,898.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CODX stock in 2026?
Our dual AI analysis gives Co-Diagnostics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CODX's free cash flow?
Co-Diagnostics, Inc.'s operating cash flow is $-22.9M, with capital expenditures of $568.1K. FCF margin is -6,555.5%.
How does CODX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,898.5% (avg: 12%), ROE -53.1% (avg: 15%), current ratio 3.81 (avg: 2).